Header Logo

Mary Fidler

Concepts (128)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Non-Small-Cell Lung
9
2024
106
2.100
Why?
Lung Neoplasms
10
2024
247
2.040
Why?
Erlotinib Hydrochloride
1
2018
7
0.540
Why?
Inflammation Mediators
1
2018
37
0.530
Why?
Carcinoma, Squamous Cell
5
2019
70
0.530
Why?
Drug Resistance, Neoplasm
1
2018
42
0.520
Why?
Pneumonectomy
2
2015
34
0.510
Why?
Biomarkers
1
2018
294
0.480
Why?
Neoadjuvant Therapy
3
2016
23
0.470
Why?
Social Class
1
2014
24
0.410
Why?
Antineoplastic Combined Chemotherapy Protocols
4
2021
105
0.390
Why?
Chemoradiotherapy
5
2016
17
0.380
Why?
Aged
11
2024
4000
0.350
Why?
Immunotherapy
2
2021
27
0.340
Why?
Female
14
2024
6974
0.330
Why?
Male
13
2024
6815
0.320
Why?
Neoplasm Staging
7
2024
168
0.310
Why?
Antineoplastic Agents, Immunological
2
2021
11
0.300
Why?
Humans
17
2024
12240
0.290
Why?
Antibodies, Monoclonal, Humanized
2
2019
40
0.280
Why?
Oropharyngeal Neoplasms
2
2019
9
0.270
Why?
Head and Neck Neoplasms
2
2021
57
0.270
Why?
Antineoplastic Agents
2
2022
99
0.270
Why?
Middle Aged
9
2024
4043
0.260
Why?
Biomarkers, Tumor
2
2021
101
0.260
Why?
Adenocarcinoma
2
2018
61
0.240
Why?
Body Composition
1
2024
43
0.210
Why?
Prognosis
3
2021
363
0.200
Why?
Survival Rate
3
2018
152
0.190
Why?
Programmed Cell Death 1 Receptor
2
2021
9
0.190
Why?
Maytansine
1
2022
2
0.180
Why?
Immunoconjugates
1
2022
6
0.180
Why?
Body Weight
2
2024
72
0.180
Why?
Neoplasm Recurrence, Local
1
2021
69
0.170
Why?
Neoplasms
1
2022
94
0.170
Why?
Autoantibodies
1
2021
29
0.160
Why?
Retrospective Studies
4
2019
1467
0.160
Why?
Databases, Factual
3
2019
156
0.160
Why?
Breast Neoplasms
1
2022
195
0.160
Why?
Kaplan-Meier Estimate
2
2017
85
0.150
Why?
Human papillomavirus 16
1
2019
6
0.150
Why?
Biopsy, Fine-Needle
1
2019
26
0.150
Why?
Tongue Neoplasms
1
2018
10
0.140
Why?
Cohort Studies
3
2019
827
0.140
Why?
Small Cell Lung Carcinoma
1
2018
6
0.140
Why?
Carcinoma, Large Cell
1
2018
7
0.140
Why?
ErbB Receptors
1
2018
31
0.130
Why?
Protein Kinase Inhibitors
1
2018
29
0.130
Why?
Proteomics
1
2018
39
0.130
Why?
Patient Reported Outcome Measures
1
2019
165
0.130
Why?
Mutation
1
2018
175
0.130
Why?
Age Factors
2
2018
350
0.130
Why?
Leukocyte Count
1
2017
35
0.130
Why?
Lymphocytes
1
2017
30
0.120
Why?
Neutrophils
1
2017
58
0.120
Why?
Quality of Life
1
2019
261
0.120
Why?
Adult
3
2019
3557
0.120
Why?
Follow-Up Studies
1
2018
726
0.120
Why?
Treatment Outcome
5
2021
1478
0.110
Why?
Carcinoma
2
2015
34
0.110
Why?
Prospective Studies
1
2018
817
0.110
Why?
United States
2
2019
989
0.110
Why?
Prostaglandins
1
2014
2
0.110
Why?
Induction Chemotherapy
1
2014
8
0.100
Why?
Cancer Care Facilities
1
2014
6
0.100
Why?
Academies and Institutes
1
2014
6
0.100
Why?
Radiotherapy, Intensity-Modulated
1
2014
14
0.100
Why?
Parotid Gland
1
2014
11
0.100
Why?
Lymphatic Metastasis
1
2014
51
0.100
Why?
Health Services Accessibility
1
2014
43
0.100
Why?
Logistic Models
1
2014
196
0.100
Why?
Prevalence
1
2014
175
0.100
Why?
Aged, 80 and over
1
2018
2152
0.090
Why?
Therapies, Investigational
1
2011
5
0.090
Why?
Esophageal Neoplasms
1
2011
22
0.090
Why?
Combined Modality Therapy
3
2019
143
0.080
Why?
Patient Selection
2
2021
111
0.060
Why?
Disease-Free Survival
2
2018
66
0.060
Why?
Lymph Nodes
2
2016
38
0.060
Why?
Pemetrexed
2
2015
4
0.060
Why?
Body Mass Index
1
2024
221
0.050
Why?
Tumor Microenvironment
1
2022
12
0.050
Why?
Cetuximab
1
2021
2
0.040
Why?
Phototherapy
1
2021
17
0.040
Why?
B7-H1 Antigen
1
2021
4
0.040
Why?
Antigens, Neoplasm
1
2021
22
0.040
Why?
Observer Variation
1
2021
47
0.040
Why?
Survival Analysis
1
2021
99
0.040
Why?
Genetic Heterogeneity
1
2019
5
0.040
Why?
Clinical Decision-Making
1
2019
28
0.040
Why?
Reference Values
1
2019
103
0.040
Why?
Cyclin-Dependent Kinase Inhibitor p16
1
2018
19
0.040
Why?
Neoplasm Invasiveness
1
2018
34
0.040
Why?
Risk Assessment
1
2019
295
0.030
Why?
Papillomaviridae
1
2016
5
0.030
Why?
Papillomavirus Infections
1
2016
8
0.030
Why?
Radiation Pneumonitis
1
2015
2
0.030
Why?
Hemoptysis
1
2015
4
0.030
Why?
Esophagitis
1
2015
5
0.030
Why?
Etoposide
1
2015
15
0.030
Why?
Carboplatin
1
2015
11
0.030
Why?
Chest Pain
1
2015
8
0.030
Why?
Cough
1
2015
7
0.030
Why?
Paclitaxel
1
2015
25
0.030
Why?
Radiation Injuries
1
2015
15
0.030
Why?
Dyspnea
1
2015
22
0.030
Why?
Young Adult
1
2018
863
0.030
Why?
Adolescent
1
2018
989
0.030
Why?
Palliative Care
1
2015
53
0.030
Why?
Neoplasm, Residual
1
2015
5
0.030
Why?
Chemoradiotherapy, Adjuvant
1
2015
4
0.030
Why?
Lymph Node Excision
1
2015
15
0.030
Why?
Radiotherapy Dosage
1
2015
42
0.030
Why?
Glutamates
1
2014
3
0.030
Why?
Guanine
1
2014
3
0.030
Why?
Analysis of Variance
1
2015
125
0.030
Why?
Taxoids
1
2014
4
0.030
Why?
Cyclooxygenase 2
1
2014
18
0.030
Why?
Pyrroles
1
2014
15
0.030
Why?
Sulfonamides
1
2014
22
0.030
Why?
Drug Administration Schedule
1
2014
84
0.030
Why?
Patient Readmission
1
2015
48
0.030
Why?
Double-Blind Method
1
2014
166
0.030
Why?
Length of Stay
1
2015
126
0.030
Why?
Choice Behavior
1
2011
19
0.020
Why?
Digestive System Surgical Procedures
1
2011
14
0.020
Why?
Medical Oncology
1
2011
23
0.020
Why?
Disease Progression
1
2011
290
0.020
Why?
Fidler's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (128)
Explore
_
Co-Authors (16)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_